RP23-61E13.2 inhibitors represent a chemical class designed to interact with a specific biological pathway by binding to a molecular target identified by the genetic locus RP23-61E13.2. This target is typically a protein or enzyme encoded by the corresponding gene, and the inhibitors are formulated to modulate the activity of this protein. Through this interaction, the inhibitors can affect the function of the protein, leading to alterations in the associated biological processes. The chemical structures within this class are characterized by their ability to fit into the active site or another relevant binding region of the protein, which is usually shaped to accommodate certain molecules through a highly specific lock-and-key mechanism. The design of RP23-61E13.2 inhibitors takes into account the size, shape, and electronic properties of the target site, ensuring that they are complementary and capable of forming stable interactions, often through non-covalent bonds such as hydrogen bonds, ionic interactions, and hydrophobic effects.
The development and refinement of RP23-61E13.2 inhibitors involve a rigorous process of chemical synthesis and structure-activity relationship (SAR) studies. These studies help in understanding how different chemical groups and molecular architectures influence the binding affinity and selectivity of the inhibitors towards their target. A high degree of selectivity is crucial for the efficacy of the inhibitors in modulating the activity of the target protein without affecting other proteins with similar structures. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often employed to gain insights into the molecular interactions at play. The physicochemical properties, such as solubility, stability, and permeability, are also optimized to ensure that the inhibitors maintain their integrity and effectiveness under physiological conditions. The inhibitors in this class are the result of a convergence of various scientific disciplines, including medicinal chemistry, biochemistry, and molecular biology, which collectively contribute to the design and optimization of these molecules.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that can indirectly inhibit RP23-61E13.2 by blocking the EGFR tyrosine kinase activity, which may be upstream in signaling pathways involving RP23-61E13.2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTOR signaling pathway. Since mTOR can regulate various proteins and processes, including those potentially involving RP23-61E13.2, inhibition can lead to reduced function of RP23-61E13.2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can prevent the phosphorylation and activation of AKT, which may have downstream effects leading to the inhibition of RP23-61E13.2. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor that can halt cell cycle progression, potentially affecting the activity of RP23-61E13.2 if its function is related to cell cycle control. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that may indirectly inhibit RP23-61E13.2 by interfering with the MAPK/ERK signaling pathway which could affect proteins regulated by this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor with targets that include VEGFR and PDGFR, potentially influencing angiogenesis and cell survival pathways that RP23-61E13.2 could be involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 which can alter the MAPK/ERK pathway, possibly affecting the functional activity of RP23-61E13.2 if it is a downstream effector. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect the degradation of proteins, which might influence the stability and function of RP23-61E13.2. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that can affect the BCR-ABL signaling pathway and potentially other kinases that could indirectly influence the activity of RP23-61E13.2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may prevent the activation of transcription factors and other proteins that are involved in pathways where RP23-61E13.2 has a role. | ||||||